Skip to main content
Public healthcare officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 to check if you are unsure if something is a scam or visit ScamShield (opens in new tab) for more information.

Cardiovascular Disease National Collaborative Enterprise (CADENCE)

National Cardiovascular Clinical Trials Network

Discover how Singapore's cardiovascular clinical trial units are unified under one network to advance heart disease research and improve patient outcomes.

Last updated on 8 July 2026

CADENCE's National Cardiovascular Clinical Trials Network brings together existing cardiovascular (CV) clinical trial units across Singapore e.g., National University Heart Centre Singapore (NUHCS), National Heart Centre Singapore (NHCS), Tan Tock Seng Hospital (TTSH), Changi General Hospital (CGH), Sengkang General Hospital (SKH), Khoo Teck Puat Hospital (KTPH) and Ng Teng Fong General Hospital (NTFGH) to function as one to support mechanistic early-phase multi-site clinical trials across Singapore.

This platform will partner with other coordinating bodies being developed by the Singapore Clinical Research Institute (SCRI) (opens in new tab) across all the clinical domains.

The platform, in collaboration with sister unit SCRI, has also facilitated in the setup of the Singapore's Clinical Trials Portal (CTSG. (opens in new tab) is crafted to cater to patients, caregivers, clinical investigators and companies by making clinical trial information more accessible and comprehensible. By demystifying the clinical trial landscape, CTSG aims to encourage greater interest in clinical trials, fostering innovation and improving health outcomes.

In addition, the National CV Biostatistics and Bioinformatics Unit established will partner with other business units within the Consortium for Clinical Research and Innovation, Singapore (CRIS) to scale-up biostatistics and bioinformatics capabilities at the national level.

Through this platform, we aim to:

  • Provide a centralised platform for the design, implementation, and conduct of clinical trials in cardiovascular medicine

  • Streamline the regulatory and administrative processes involved in conducting clinical trials

  • Facilitate collaboration and partnerships among researchers, clinicians, and industry leaders in cardiovascular medicine

Through this network, the research community will have a unified platform to conduct more efficient and effective clinical trials, leading to quicker development and approval of new cardiovascular therapies and interventions. This would ultimately improve patient outcomes and contribute to the prevention, diagnosis, and treatment of cardiovascular diseases.

Bold dark blue text reading PLATFORM LEADS on a light blue background with faint tech icons and a hand.

Lead:

Prof Ronald Lee Chi Hang in navy scrubs sits smiling at a desk with a keyboard, beside his title and credentials text.

Co-Lead:

Smiling man in glasses and dark suit, identified as Clin Assoc Prof David Sim, National Heart Centre Singapore.

Co-Lead:

Headshot of Dr Tong Jie Li, Consultant at Tan Tock Seng Hospital, a woman with dark hair.

Institutional Lead:

Headshot of Clin Asst Prof Lim Chiw Yeh, Consultant at National Heart Centre Singapore, smiling in a black blazer.

Institutional Lead:

Man in dark suit and tie smiling, beside text identifying him as Clinical Asst Prof Chai Siang Chew, Senior Consultant.

Institutional Lead:

Dr Sim Hui Wen, a smiling woman with long dark hair in a black blazer, listed as Consultant at National University Heart Centre Singapore.
Banner with bold dark blue text "USE CASE" on a light background with faint medical icons and a hand pointing.

AI-empowered imaging solution for earlier detection of cancer-related cardiac dysfunction

Cancer treatments, including chemotherapies and radiotherapies, increase the risk of cardiovascular disease.

Among many cancer survivors, the risk of mortality from cardiac disease may be higher than the cancer itself. Consequently, there has been increasing interest in detecting cancer therapy-associated cardiac dysfunction (CTRCD) early so that the patients can receive appropriate heart failure treatment.

As a result, the European Society of Cardiology recently released the first-ever guidelines on cardio-oncology, intended to guide clinicians to better recognise and treat patients with CTRCD.

Through this Use Case, CADENCE aims to:

  • Evaluate the accuracy, cost-effectiveness, and patient preference of an AI-echo guided strategy as compared to standard echocardiography in the detection of CTRCD.

  • Demonstrate earlier detection of CTRCD using an AI-echo guided strategy as compared to a standard echocardiography strategy in breast cancer and lymphoma patients receiving cardiotoxic chemotherapy.

This use case is led by:

Man in suit and glasses; text: Dr Sia Ching Hui, Associate Consultant, Cardiology, NUH Heart Centre Singapore.

Co-lead

Asst Prof Jasper Tromp in a dark suit, arms crossed, smiling, identified as a public health specialist at Duke-NUS.

Co-lead

Dr Ng Choon Ta, smiling man wearing glasses and a navy suit, listed as Senior Consultant at National Heart Centre Singapore.
A mostly white rectangular banner with a faint light gray pixel cross pattern in the far right corner.